Dalbavancin for outpatient parenteral antimicrobial therapy of skin and soft tissue infections in a returning traveller

Proposal for novel treatment indications
  • Johannes Mischlinger
  • Heimo Lagler
  • Nicole Harrison
  • Michael Ramharter
short report

Summary

Skin and soft tissue infections (SSTIs) are among the most common health problems in travellers returning from tropical and subtropical countries. Importantly, the prevalence of Staphylococcus aureus, the most common pathogen for purulent SSTIs, with specific drug resistance, such as methicillin resistant Staphylococcus aureus (MRSA) and those expressing virulence genes, such as Panton-Valentine-leukocidin is higher in tropical regions than in most high resource settings. This poses challenges for the empirical antimicrobial treatment of SSTIs in returning travellers. This short report describes a patient with a recent travel history to Hong Kong, Singapore and the Philippines who presented with multiple mosquito bites on both upper extremities and secondary bacterial superinfection. He had previously been prescribed oral beta-lactam antimicrobial therapy but lacked adherence to this treatment. Based on the risk for MRSA infection and problems with treatment adherence to oral therapy an outpatient parenteral antimicrobial therapy with dalbavancin was administered on days 0 and 7. Microbiological culture confirmed presence of MRSA and clinical follow-up demonstrated complete remission of the SSTI within 2 weeks. Dalbavancin is a promising treatment option for empirical parenteral treatment of SSTIs in returning travellers, a population at high risk for beta-lactam resistant S. aureus skin infections.

Keywords

Dalbavancin MRSA Staphylococcus aureus SSTI Travel medicine 

References

  1. 1.
    Hochedez P, Canestri A, Lecso M, Valin N, Bricaire F, Caumes E. Skin and soft tissue infections in returning travelers. Am J Trop Med Hyg. 2009;80(3):431–4.PubMedGoogle Scholar
  2. 2.
    Adler A, Temper V, Block CS, Abramson N, Moses AE. Panton-valentine Leukocidin-producing staphylococcus aureus. Emerging Infect Dis. 2006;12(11):1789–90.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Stenhem M, Örtqvist Å, Ringberg H, Larsson L, Olsson-Liljequist B, Hæggman S, et al. Imported Methicillin-Resistant Staphylococcus aureus, Sweden. Emerging Infect Dis. 2010;16(2):189–96.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Zanger P, Nurjadi D, Schleucher R, Scherbaum H, Wolz C, Kremsner PG, et al. Import and spread of Panton-valentine Leukocidin-positive staphylococcus aureus through nasal carriage and skin infections in travelers returning from the tropics and subtropics. Clin Infect Dis. 2012;54(4):483–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Zervos M. Treatment options for uncomplicated community-acquired skin and soft tissue infections caused by methicillin-resistant staphylococcus aureus: oral antimicrobial agents. Surg Infect (Larchmt). 2008;9(Suppl 1):s29–s34.CrossRefGoogle Scholar
  6. 6.
    Adegnika AA, Breitling LP, Agnandji ST, Chai SK, Schutte D, Oyakhirome S, et al. Effectiveness of quinine monotherapy for the treatment of Plasmodium falciparum infection in pregnant women in Lambarene, Gabon. Am J Trop Med Hyg. 2005;73(2):263–6.PubMedGoogle Scholar
  7. 7.
    Mischlinger J, Agnandji ST, Ramharter M. Single dose treatment of malaria – current status and perspectives. Expert Rev Anti Infect Ther. 2016;14(7):669–78.CrossRefPubMedGoogle Scholar
  8. 8.
    The malERA Consultative Group on Health Systems and Operational Research. A research agenda for malaria eradication: health systems and operational research. PLoS Med. 2011;8(1):e1000397.CrossRefPubMedCentralGoogle Scholar
  9. 9.
    Biedenbach DJ, Bell JM, Sader HS, Turnidge JD, Jones RN. Activities of dalbavancin against a worldwide collection of 81,673 gram-positive bacterial isolates. Antimicrob Agents Chemother. 2009;53(3):1260–3.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Billeter M, Zervos MJ, Chen AY, Dalovisio JR, Kurukularatne C. Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008;46(4):577–83.CrossRefPubMedGoogle Scholar
  11. 11.
    Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370(23):2169–79.CrossRefPubMedGoogle Scholar
  12. 12.
    Eckmann C, Lawson W, Nathwani D, Solem CT, Stephens JM, Macahilig C, et al. Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria. Int J Antimicrob Agents. 2014;44(1):56–64.CrossRefPubMedGoogle Scholar
  13. 13.
    Malabarba A, Goldstein BP. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother. 2005;55(Suppl 2):ii15–ii20.PubMedGoogle Scholar
  14. 14.
    Scott LJ. Dalbavancin: a review in acute bacterial skin and skin structure infections. Drugs. 2015;75(11):1281–91.CrossRefPubMedGoogle Scholar
  15. 15.
    Candel FJ, Julian-Jimenez A, Gonzalez-Del Castillo J. Current status in outpatient parenteral antimicrobial therapy: a practical view. Rev Esp Quimioter. 2016;29(2):55–68.PubMedGoogle Scholar
  16. 16.
    Seaton RA, Barr DA. Outpatient parenteral antibiotic therapy: principles and practice. Eur J Intern Med. 2013;24(7):617–23.CrossRefPubMedGoogle Scholar
  17. 17.
    Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr.. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–61.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Cohen PR. Community-acquired methicillin-resistant Staphylococcus aureus skin infections: implications for patients and practitioners. Am J Clin Dermatol. 2007;8(5):259–70.CrossRefPubMedGoogle Scholar
  19. 19.
    Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29(5):1128–32.CrossRefPubMedGoogle Scholar
  20. 20.
    Pechere JC, Hughes D, Kardas P, Cornaglia G. Non-compliance with antibiotic therapy for acute community infections: a global survey. Int J Antimicrob Agents. 2007;29(3):245–53.CrossRefPubMedGoogle Scholar
  21. 21.
    Fernandes M, Leite A, Basto M, Nobre MA, Vieira N, Fernandes R, et al. Non-adherence to antibiotic therapy in patients visiting community pharmacies. Int J Clin Pharm. 2014;36(1):86–91.CrossRefPubMedGoogle Scholar
  22. 22.
    Yamamoto Y, Kadota J, Watanabe A, Yamanaka N, Tateda K, Mikamo H, et al. Compliance with oral antibiotic regimens and associated factors in Japan: compliance survey of multiple oral antibiotics (COSMOS). Scand J Infect Dis. 2012;44(2):93–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Galactionova K, Tediosi F, de Savigny D, Smith T, Tanner M. Effective coverage and systems effectiveness for malaria case management in Sub-Saharan African countries. PLOS ONE. 2015;10(5):e0127818.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Hill J. Adherence with drug therapy in the rheumatic diseases part two: measuring and improving adherence. Musculoskeletal Care. 2005;3(3):143–56.CrossRefPubMedGoogle Scholar
  25. 25.
    Sondo P, Derra K, Diallo-Nakanabo S, Tarnagda Z, Zampa O, Kazienga A, et al. Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malar J. 2015;14:325.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Lotsch F, Auer-Hackenberg L, Groger M, Rehman K, Morrison V, Holmes E, et al. Adherence of patients to long-term medication: a cross-sectional study of antihypertensive regimens in Austria. Wien Klin Wochenschr. 2015;127(9–10):379–84.CrossRefPubMedGoogle Scholar
  27. 27.
    World Health Organisation. Guidelines for the treatment of malaria, 3rd ed. Geneva: WHO; 2015.Google Scholar
  28. 28.
    Kremsner PG, Radloff P, Metzger W, Wildling E, Mordmuller B, Philipps J, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother. 1995;39(7):1603–5.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ramdeen S, Boucher HW. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Expert Opin Pharmacother. 2015;16(13):2073–81.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Leuthner KD, Buechler KA, Kogan D, Saguros A, Lee HS. Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag. 2016;12:931–40.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J. A randomized clinical trial of single-dose versus weekly Dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62(5):545–51.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria 2017

Authors and Affiliations

  1. 1.Department of Medicine I, Division of Infectious Diseases and Tropical MedicineMedical University of ViennaViennaAustria
  2. 2.Centre de Recherches Médicales de LambarénéLambarénéGabon
  3. 3.Institut für TropenmedizinUniversität TübingenTübingenGermany

Personalised recommendations